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INCIDENCE OF ADVERSE REACTIONS TO 
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PSYCHOPHARMACOLOGICAL AGENTS DURING 
EARLY PHASE OF THERAPY 
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Five hundred and ninety two patients attending a psychiatric departmeM as out^^ 
were included in this study. Details regarding age, sex, diagnosis and drugs prescribed were entered 
in aproforma. The information regarding drugs prescribed, dosage and the types of reactions were 
noted. All patients were followed up for a period of 3 to 4 weeks. Incidence of adverse reactions was 
calculated as percentage of the total number of prescriptions of the same group of drugs. The incidence 
of reactions to antipsychotic and antidepressants ranged from 35 to 46.9%. The incidence of reactions 
to haloperidol was higher than the reactions to other drugs. Antianxiety drugs were found to produce 
only minimal reactions. Two or more drugs prescribed together was associated with a higher incidence 
of reactions. Among the 193 patients who were reported to have reactions, 65.8% had extrapyramidal 
symptoms. The frequency of these reactions were highest with antipsychotic drugs haloperidol, 
chlorpromazine, trifluoperazine and thioridazine in that order. Dystonic reactions were reported within 
one to two days after the initiation of therapy in a large group of patients. Anticholinergic side effects 
were associated with prescription of tricyclic antidepressants andphenothiazines. Drowsiness, giddi-
ness and postural hypotension were the other reactions associated with tricyclics. 
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INTRODUCTION 
Many psychiatric patients are required to be on 
long term therapy with drugs and many of them 
develop adverse effects. Adverse reactions are one 
of the main factors which prompt patients to discon-
tinue the medications. These also frighten the rela-
tives who at times actively encourage patients to 
discontinue the medication. Awareness of these 
reactions and measures to combat them are impor-
tant for the practicing physician. This study high-
lights the incidence and profile of common reactions 
developing during early phase of treatment and fac-
tors influencing these reactions. 
MATERIALS AND METHODS 
Patients attending the outpatient clinic and those 
admitted in the wards of a psychiatry unit were 
included in this study. All patients were followed up 
for a minimum period of 3 to 4 weeks. The study 
period involves two six months periods. Details 
regarding age, sex, diagnosis and drugs prescribed 
were entered in a proforma prepared for this study. 
Reactions which were disturbing to the patients were 
reported by them. In addition, the reactions which 
were observed by the investigator were also 
recorded. These observations were guided by a 
check-list which included an the known side effects 
of psychopharmacological agents as reported Jo 
literature. Patients attending outpatient clinic were 
followed up during their subsequent visits. 
Incidence of adverse reactions were calculated as 
percentage of the total number of prescriptions of the 
same group of drugs. In each group, age and sex of 
patients who were receiving these drugs were noted. 
Reactions were grouped into various categories such 
as acute dystonia, other extrapyramidal symptoms 
and anticholinergic effects. Number of occurrence 
of each reaction was noted and the total frequency 
of each group of reactions were calculated. Propor-
tion test was done to compare two group to deter-
mine significance. 
RESULTS 
Of the 592 patients included in this study, 322 
were males and 270 were females. Diagnostic details 
of this group of patients are presented in Table 1'; 193 
patients in this group of 592 developed adverse 
reactions. The overall incidence of adverse reactions 
in this group is 32.6%. 
The pattern of prescriptions show that the mam 
group of drugs prescribed were antipsychotics and 
antidepressants. The major group of antipsychotics 
prescribed were haloperidol and phenothiazine. 
Among the phenothiazine the most frequently KURUVILLA & KURUVILLA 
Table 1 
Morbidity pattern of patients included in this study 
Table2 
Age and sex distribution of patients with drug reactions 
Disease group  Sex 
Male Female 
Total 
No. % 
Affective disorders 
MOP mania and 
MDP circular currently 
manic 
MDP depression 
and MDP currently 
depressed 
Schizophrenia 
Reactive psychoses 
Paranoid state 
Neurotic depression 
Obsessive compulsive 
neurosis 
Anxiety, panic disorder 
Neuroses (Not otherwise 
specified) 
Alcohol dependence 
Neurological disorders 
associated with 
behavioral changes 
Total 
182 
74 
108 
24 
10 
9 
44 
11 
8 
11 
12 
11 
322 
174 
66 
108 
16 
13 
7 
31 
4 
4 
11 
-
10 
270 
356 
140 
216 
40 
23 
16 
75 
15 
12 
22 
12 
21 
592 
60.1 
23.6 
36.5 
6.8 
3.9 
2.7 
12.7 
2.5 
2.0 
3.7 
2.0 
3.5 
99.9 
Age group of patients: 20-39 yrs 61.4%; 49-59 yrs 22.6 
%; betow 20 yrs 11.4%; above 60 yrs 4.6%. 
prescribed drug was chlorpromazine (75%). Tri-
fluoperazine, thioridazine and fluphenazine 
decanoate were the other members of the 
phenothiazine group which were prescribed. The 
major group of antidepressants prescribed were 
tricyclics of which amitriptyline and imipramine 
were the most frequently prescribed drugs. 
Dothepin, doxepin and clomipramine were the other 
tricyclic drugs prescribed. The major antianxiety 
drugs were benzodiazepines (chlordiazepoxide and 
diazepam). The antimanic drugs used were lithium 
and carbamazepine. The details regarding age and 
sex of patients developing reactions are presented in 
Table 2. 
The incidence of reactions to various groups of 
drugs are presented in Fig 1. The overall incidence 
to the most commonly prescribed drugs viz antip-
sychotics and antidepressants ranged from 35 to 
46.9%. The incidence of reactions of haloperidol 
was significantly higher (p<0.001) than the reac-
tions associated with phenothiazine. Patients who 
were prescribed chlorpromazine reported an in-
Age in Male 
years N R 
Upto20 37 8(21.6) 
20-39 218 73(33.4) 
40-59 65 16(24.6) 
Above 60 15 6(40) 
Female 
N R 
30 16(53.3) 
146 52(35,6) 
69 20(28.9) 
12 2(16,7) 
Total 
N R 
67 21(35.8) 
364 125(34.3) 
134 36(26.8) 
27 8 (29.6) 
N indicates the number of patients observed and R 
indicates the number of reactions present. Incidence is 
expressed as a percentage of total number of patients 
receiving drugs belonging to the same age and sex 
group. Incidence in the male patients 32% and female 
patients 33%. Incidence in the age group below 40 yrs 
34.6% and in the group above 40 yrs is 27.3%. The 
incidence in the younger age is higher than the older age 
groups, but this does not reach the level of significance. 
Table 3 
Incidence of reactions and number of drugs 
Drugs Total One drug Two or more 
No. % No. % p value 
All drugs 
(whole group) 592 100 23.8 93 53.7 0.001 
Haloperidol 162 12 27.2 77 65.2 0.001 
Chlorpromazine 158 19 21.5 39 55.7 0.001 
Tricyclic anti-
depressants 322 60 25.0 50 62.0 0.002 
Total number of patients receiving drugs for each group 
are indicated. Number of patients developing or not 
developing reactions in each group were calculated 
(Reactions + or -). Incidence of reactions in each group 
is calculated as a percentage of the number of patients 
prescribed the same drug either alone or in combination. 
cidence of 37% while those who were prescribed 
thioridazine and trifluoperazine had incidence of 
21.7 % and 23% respectively. The number of drugs 
prescribed, and the incidence of reactions are 
presented in Table 3. Two or more drugs prescribed 
together is associated with a higher incidence of 
reactions. 
Nature of reactions and their relation to drug 
groups: 
Extrapyramidal symptoms (EPS) were observed 
in many patients during early phase of therapy. 
These reactions included tremors, slurred speech, 
rigidity, akinesia, loss of associated movements, 
fixed posture of limbs, excessive salivation, lip 
smacking, protrusion of tongue, paucity of expres-ADVERSE REACTIONS TO PSYCHOPHARMACOLOGICAL AGENTS 
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Legend to Figure 1 
This figure is based on the following number of prescriptions, Antipsychotics 381 (Haloperidol 162, Phenothiazines 210, 
Pimozide 9); Antidepressants 325 (Tricyclics 322); Anxiolytics 34; Antimanics 37 (Lithium 29, Carbamazepine 8). 
Incidence is expressed as a percentage on the basis of number of patients developing reactions among these who 
were prescribed the same drugs. 
sion, slopping gait and difficult in swallowing. 
Among the 193 patients who were reported to have 
adverse reactions, 65.8% had extrapyramidal 
symptoms. Male to female ratio in this group was 
1:1.08. The age distribution of this group of patients 
show that there was a higher incidence in patients 
below 40 yrs (84%). The frequency of these reac-
tions were highest with haloperidol, 
chlorpromazine, trifluoperazine and thioridazine in 
that order. Some patients on tricyclics and an-
timanics also developed EPS - but such patients were 
invariably on antipsychotics also at the same time. 
Tremors were reported as a reaction by 7% of 
patients who were prescribed imipramine. Half of 
these had imipramine as the only drug while the 
remaining 50% had combination of imipramine and 
phenothiazine. 
Extrapyramidal symptoms were reported as a 
disturbing side-effect by the patients during initial 
phase of therapy. In 65% of those reported, onset of 
these reactions were noted after one week, while 
35% had noted these symptoms within one week 
(2-5 days). The dose of chlorpromazine in the group 
of patients with EPS ranged from 200-600 mg; and 
that of haloperidol 5-10 mg. Most of these patients 
responded to treatment with anticholinergic drugs 
like trihexiphendyl or kemadrine. Very few patients 
only required reduction of dose of antipsychotic. 
Among the various extrapyramidal symptoms, 
dystonia was the most disturbing one to the patient. 
Dystonic reactions reported by patients include turn-
ing of the neck to one side, inability to protrude 
tongue, pulling sensation in the neck and oculogyric 
crisis. Analysis was done to determine various fac-
tors associated with this reaction. Acute dystonia 
was frequently observed as a reaction during early 
phase of therapy. Onset of this reaction in 80% of 
the patients was within one to two days after the KURUVILLA & KURUV1LLA 
Table 4 
Nature of reactions and drug groups 
Reaction 
Extrapyramidal 
symptoms 
(EPS) 
Dystonia* 
(alone) 
Anticholinergic 
reactions 
Dry mouth 
Constipation 
Blurring of vision 
Retention of urine 
Giddiness 
Postural hypotension 
Tremors 
Drug group 
all drugs 
antipsychotics 
antidepressants 
antimanic 
all drugs 
antipsychotics 
all drugs 
tricyclics 
tricyclics 
tricyclics 
tricyclics 
tricyclics 
all drugs 
tricyclics 
all drugs 
all drugs 
antipsychotics 
tricyclics 
Incidence % 
21.5 
30.0 
25.0 
7.0 
6.7 
6.7 
17.0 
36.3 
15.2 
9.0 
2.1 
0.9 
5.4 
9.0 
1.7 
7.6 
6.8 
7.4 
The most common type of reactions are presented. In 
patients who developed EPS, one drug alone was 
prescribed for 44%, more than one drug was prescribed 
for 56% of these patients. 
* All patients who developed dystonia had combinations 
of antipsychotics with arrtimanics or tricyclics. 
initiation of therapy. The male to female ratio was 
2:1 in this group. Age distribution of these patients 
showed that 27 out of 40 patients were below the age 
of 30 yrs. 66% of these patients had two or more 
drugs while 33% had single drug. The most fre-
quently used combination was haloperidol and 
phenothiazine (66%). Injection haloperidol in com-
bination with oral haloperidol and/or phenothiazine 
appeared to enhance the onset of acute dystonic 
reaction. The duration of acute dystonic reaction 
ranged from 10 to 30 minutes. These patients 
responded well to treatment with injection phener-
gan (IM or IV). In most patients the improvement 
was dramatic. Anticholinergic side effects were as-
sociated with prescription of tricyclic antidepres-
sants and phenothiazine. None of the patients with 
these reactions required any specific treatment. 
Skin reactions like rashes, were reported by two 
patients who were prescribed chlorpromazine. 
These reactions subsided on withdrawal of the drug. 
Polyuria and polydypsia was reported by one 
patients who was given (1050 mg) of lithium (single 
drug). Erectile dysfunction was reported by two 
patients who were on clomipramine. An episode of 
seizure occurred in one patient who was on treat-
ment for delusional depression, with imipramine, 
chlorpromazine, and oral haloperidol (40 mg). 
Seizures responded to treatment with phenytoin. 
Detailed analysis of these reactions could not be 
carried out since the number of patients reporting 
these reactions were very few. 
DISCUSSION 
The incidence of adverse reactions to most group 
of drugs is 35% or more with the exception of 
anxiolytics. This incidence is lower than the in-
cidence reported in some other studies (Schmidt et 
al, 1984). This study includes report of reactions 
from 462 outpatients and 130 inpatients. It is likely 
that some of the reactions were not observed or 
reported by outpatients. Differences in rates of in-
cidence have been reported by Grohmann et al 
(1984) when system of monitoring involves inten-
sive drug monitoring (IDM) and organized spon-
taneous reporting system (OSR). The relative 
frequency of Grade III ADR was similar for 
neuroleptic and antidepressants (54% and 53% in 
OSR) in the study reported by Grohmann et al 
(1984). Inpatients monitored by IDM had a high 
incidence rate in their study, although life threaten-
ing ADR were of equal intensity by both system of 
monitoring. 
In the present study, inpatients are noticed to have 
a higher incidence (39%) of reactions as compared 
to outpatients (24%). This may be attributed to a 
better opportunity for observations by staff in addi-
tion to the report by relatives who also were required 
to stay with the patients in this hospital. The period 
of follow up is 3 to 4 weeks. It is likely that some of 
the reactions such as weight gain are not noticed by 
patients during this period. Similarly polyuria and 
polydypsia which are usually delayed reactions to 
lithium therapy was reported by one patient only in 
the early phase of treatment. 
Number of drugs prescribed concomitantly in-
creases the incidence of adverse reactions (Table 3). 
The pharmacological effects of two antipsychotics 
like haloperidol and phenothiazine may produce 
additive effects of dopaminergic blockade and lead 
to high incidence of extra pyramidal symptoms. 
Addonizio et al (1988) have suggested that the addi-
tion of lithium to neuroleptic alters the phar-
macokinetics. This may contribute to the increased 
incidence of extrapyramidal symptoms. There is no 
evidence to suggest that such combinations may add ADVERSE REACTIONS TO PSYCHOPHARMACOLOGICAL AGENTS 
to the therapeutic efficacy. Therefore the ad-
visability of such combinations which would result 
in increased EPS becomes highly questionable. 
Murphy and Hartman (1988) have hypothesized that 
the pathological changes produced by underlying 
disease state may contribute to EPS. These authors 
have suggested that the patients with affective dis-
order may be more vulnerable than schizophrenic 
patients to the development of EPS with the com-
bination of lithium and neuroleptic. 
Among the antipsychotics prescribed haloperidol 
is associated with the highest incidence of reactions 
which indicate that the potency of the drug is also 
another factor which influence the incidence of reac-
tions. The most disturbing symptoms reported by 
patients who were prescribed antipsychotic drugs 
were the extrapyramidal symptoms. Parkinsonism 
and inconvenient sedation are mentioned as the 
severe reactions responsible for drug withdrawal 
(Schmidt et al, 1984). It is important to recognize 
these reactions early and also to provide sufficient 
information to the patients and relatives when drug 
therapy is initiated (Hermesh et al, 1985). The aim 
of therapy should be to keep the incidence and 
severity of these reactions as low as possible. Acute 
dystonic reactions are known to be frightening to the 
patient although the incidence of this reaction is low 
(Barach et al, 1989). Young male patients are likely 
to develop this reaction. Prophylactic anticholiner-
gic treatment during early phase of therapy is jus-
tified in such patients, particularly those receiving 
high-potency drugs (Jack & Robert, 1989). 
Akathisia described as a subjective sense of rest-
lessness has been observed in some patients. 
Akathisia associated with increased doses of 
neuroleptics has been attributed to worsening of 
Tourette's disorder by Weiden and Brunn (1987). 
Akathisia has been viewed as a forerunner of tardive 
dyskinesia by some authors (Goswami & Chan-
nabasavanna, 1984). This reaction is reported to be 
less likely to respond to anticholinergic treatment. 
The anticholinergic side effects most frequently as-
sociated with tricyclics and antipsychotics are less 
disturbing to the patient although the incidence of 
these reactions is high. 
In summary this study presents the incidence and 
profile of reactions to commonly prescribed 
psychopharmacological agents. Phar-
macoepidemiological methods for identifying and 
quantifying adverse reactions can assist therapeutic 
decisions in patients with special risk of side effects 
to psychotropic drugs and also help in the education 
of patients and relatives (Leber, 1983; Chaturvedi, 
1985; Zito & Craig, 1988). Such information may 
help to decrease the noncompliance with regular 
medication which is one of the most troublesome 
problems in the treatment of psychiatric patients. 
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